{
    "clinical_study": {
        "@rank": "131314", 
        "arm_group": [
            {
                "arm_group_label": "deferasirox dispersible tablet", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "deferasirox film-coated tablet", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the new film-coated tablet formulation to the currently approved dispersible tablet\n      formulation with regards to overall safety, Gastrointestinal (GI) tolerability,\n      palatability, satisfaction and compliance"
        }, 
        "brief_title": "Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Iron Overload Due to Transfusion-dependant Anemias", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Iron Overload"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients aged \u2265 10 years\n\n          -  Patients with transfusion-dependent thalassemia and iron overload, requiring\n             deferasirox DT at doses of \u2265 30 mg/kg/day as per the investigator's decision OR\n             Patients with very low, low or intermediate (int) risk myelodysplastic syndrome (MDS)\n             and iron overload, requiring deferasirox DT at doses of \u2265 20 mg/kg/day as per the\n             investigator's decision.\n\n          -  History of transfusion of at least 20 PRBC units and anticipated to be transfused\n             with at least 8 units of PRBCs annually during the study\n\n          -  Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the\n             mean value will be used for eligibility criteria).\n\n        Exclusion Criteria:\n\n          -  Creatinine clearance below the contraindication limit in the locally approved\n             prescribing information. Creatinine clearance will be estimated from serum creatinine\n             at screening Visit 1 and screening Visit 2 and the mean value will be used for\n             eligibility criteria.\n\n          -  Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and screening\n             Visit 2 (the mean value will be used for eligibility criteria).\n\n          -  ALT (SGPT) > 5xULN, unless if LIC confirmed as <10 mg Fe/dw within 6 months prior to\n             screening visit 1.\n\n          -  Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5\n             mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.\n\n          -  Patients with significant impaired gastrointestinal (GI) function or GI disease that\n             may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,\n             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel\n             resection)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125877", 
            "org_study_id": "CICL670F2201"
        }, 
        "intervention": [
            {
                "arm_group_label": "deferasirox dispersible tablet", 
                "description": "Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.", 
                "intervention_name": "Deferasirox dispersible tablet", 
                "intervention_type": "Drug", 
                "other_name": "ICL670, DT (dispersible tablet)"
            }, 
            {
                "arm_group_label": "deferasirox film-coated tablet", 
                "description": "Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.", 
                "intervention_name": "Defearisox film-coated tablet", 
                "intervention_type": "Drug", 
                "other_name": "ICL670, FCT (film-coated tablet)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deferasirox"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Iron overload", 
            "Chelation", 
            "Thalassemia", 
            "Myelodysplastic syndrome (MDS)", 
            "Transfusional hemisiderosis", 
            "Deferasirox", 
            "ICL670", 
            "Dispersible tablet", 
            "Film-coated tablet"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Children's Hospital Oakland Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "lneumayr@mail.cho.org", 
                    "last_name": "Lynne Neumayr", 
                    "phone": "510-428-3651"
                }, 
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Children's Hospital Oakland Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Elliott P. Vichinsky", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868-3874"
                    }, 
                    "name": "Children's Hospital of Orange County Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "bgonzales@choc.org", 
                    "last_name": "Brandy Gonzales", 
                    "phone": "714-509-8824"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868-3874"
                    }, 
                    "name": "Children's Hospital of Orange County Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Geetha Puthenveetil", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "Nancy_Licciardi@rush.edu", 
                    "last_name": "Nancy Licciardi", 
                    "phone": "312-563-3347"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center 3"
                }, 
                "investigator": {
                    "last_name": "Jamile Shammo", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dmuntz@luriechildrens.org", 
                    "last_name": "Devin Muntz", 
                    "phone": "312-227-4824"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Alexis Thompson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pamela.boardman@childrens.harvard.edu", 
                    "last_name": "Pamela Boardman", 
                    "phone": "617-355-2901"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Children's Hospital Boston Department of Hematology"
                }, 
                "investigator": {
                    "last_name": "Ellis Neufeld", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Weill Cornell Medical College-Cornell University Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "maj7002@med.cornell.edu", 
                    "last_name": "Maria Jimenez", 
                    "phone": "212-746-3446"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Weill Cornell Medical College-Cornell University Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Patricia Giardina", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4399"
                    }, 
                    "name": "Children's Hospital of Philadelphia Onc. Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "stanleyh1@email.chop.edu", 
                    "last_name": "Helen Stanley", 
                    "phone": "267-426-5602"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4399"
                    }, 
                    "name": "Children's Hospital of Philadelphia Onc. Dept"
                }, 
                "investigator": {
                    "last_name": "Janet L. Kwiatkowski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "A-4010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille cedex", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille C\u00e9dex 5", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hazmiyeh", 
                        "country": "Lebanon"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "50589"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pulau Pinang", 
                        "country": "Malaysia", 
                        "zip": "10990"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "06726"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e9xico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "02990"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e9xico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "06720"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moskow", 
                        "country": "Russian Federation", 
                        "state": "Russia", 
                        "zip": "117198"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "125167"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rostov on Don", 
                        "country": "Russian Federation", 
                        "zip": "344022"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dammam", 
                        "country": "Saudi Arabia", 
                        "zip": "15215"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dammam", 
                        "country": "Saudi Arabia", 
                        "zip": "40145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeddah", 
                        "country": "Saudi Arabia", 
                        "zip": "21589"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riyadh", 
                        "country": "Saudi Arabia", 
                        "zip": "11472"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riyadh", 
                        "country": "Saudi Arabia", 
                        "zip": "11211"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28033"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Al Ain - Abu Dhabi", 
                        "country": "United Arab Emirates"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubai", 
                        "country": "United Arab Emirates", 
                        "zip": "9115"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "France", 
                "Germany", 
                "Lebanon", 
                "Malaysia", 
                "Mexico", 
                "Russian Federation", 
                "Saudi Arabia", 
                "Spain", 
                "Thailand", 
                "United Arab Emirates"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Austria: Agency for Health and Food Safety", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "France: National Agency for the Safety of Medicines and Health Products (MSNA)", 
                "Greece: National Organization of Medicines", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Lebanon: Ministry of Public Health", 
                "Saudi Arabia: Ministry of Health", 
                "Saudi Arabia: Ethics Committee", 
                "Thailand: Food and Drug Administration", 
                "Malaysia: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Mexico: Ministry of Health", 
                "Greece: Ministry of Health and Welfare", 
                "Thailand: Ministry of Public Health", 
                "Russia: Ethics Committee", 
                "United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health", 
                "United Arab Emirates: General Authority for Health Services for Abu Dhabi"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As measured by frequency and severity of adverse events (AEs) and changes in laboratory values from baseline (serum creatinine,creatinine clearance, Alanine aminotransferase (ALT), Aspartate aminotransferase  (AST), platelets, red blood cells (RBC) and white blood cell (WBC)) from day of patient's informed consent until 31 days after last dose of study medication.", 
            "measure": "Overall safety", 
            "safety_issue": "Yes", 
            "time_frame": "Screening visit thru post-treatment period - 30 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "(diarrhea, constipation, nausea, vomiting, abdominal pain)", 
                "measure": "Frequency of selected GI AEs (Gastro-Intestinal Adverse Events)", 
                "safety_issue": "Yes", 
                "time_frame": "on-treatment period (Day 1 - safety follow-up) - 28 weeks"
            }, 
            {
                "description": "AUCtau, AUClast, Cmax, Tmax at week 1 and week 3 (only applies to PK subset A) C2hr and Ctrough at week 3, 13 and 21 for all study patients", 
                "measure": "Pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "week 1, 3, 13 and 21"
            }, 
            {
                "description": "analyses will be performed for both formulations for each domain score at scheduled visits (Week 2, Week 3, Week 13, visit 777 (end of treatment) and their absolute changes at Week 13 and 777 from Week 2.", 
                "measure": "Domain scores of treatment satisfaction and palatability over time", 
                "safety_issue": "No", 
                "time_frame": "Week 2, 3, 13 and end of treatment (week 24 or within 7 days of last dose)"
            }, 
            {
                "description": "weekly average scores of daily GI symptom scores: diarrhea, constipation, nausea, vomiting and abdominal pain, and weekly average frequencies of daily bowel movement, bowel movement related with diarrhea and accidental bowel movement will be summarized over time by descriptive statistics for both formulations.", 
                "measure": "Weekly average of daily scores of GI diary", 
                "safety_issue": "Yes", 
                "time_frame": "Weekly (screening thru end of treatment visit) - 26 weeks"
            }, 
            {
                "description": "For the daily compliance questionnaire, three dimensions of medication compliance: whether the study medication is consumed, when the medication is consumed, and whether the medication is consumed with or without food will be summarized over time by descriptive statistics for both formulations.", 
                "measure": "Relative consumed film-coated tablet (FCT)/dispersible tablet (DT) counts. Patient-reported medication consumption", 
                "safety_issue": "No", 
                "time_frame": "Daily (day 1/visit 3 - last visit) 24 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}